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Short QT syndrome variant 1 (SQT1) arises due to gain-of-function mutations to
the human Ether-à-go-go-Related Gene (hERG), which encodes the α subunit of
channels carrying rapid delayed rectifier potassium current, IKr. In addition to QT interval
shortening and ventricular arrhythmias, SQT1 is associated with increased risk of atrial
fibrillation (AF), which is often the only clinical presentation. However, the underlying
basis of AF and its pharmacological treatment remain incompletely understood in
the context of SQT1. In this study, computational modeling was used to investigate
mechanisms of human atrial arrhythmogenesis consequent to a SQT1 mutation, as well
as pharmacotherapeutic effects of selected class I drugs–disopyramide, quinidine, and
propafenone. A Markov chain formulation describing wild type (WT) and N588K-hERG
mutant IKr was incorporated into a contemporary human atrial action potential (AP)
model, which was integrated into one-dimensional (1D) tissue strands, idealized
2D sheets, and a 3D heterogeneous, anatomical human atria model. Multi-channel
pharmacological effects of disopyramide, quinidine, and propafenone, including binding
kinetics for IKr/hERG and sodium current, INa, were considered. Heterozygous and
homozygous formulations of the N588K-hERGmutation shortened the AP duration (APD)
by 53 and 86ms, respectively, which abbreviated the effective refractory period (ERP)
and excitation wavelength in tissue, increasing the lifespan and dominant frequency
(DF) of scroll waves in the 3D anatomical human atria. At the concentrations tested
in this study, quinidine most effectively prolonged the APD and ERP in the setting of
SQT1, followed by disopyramide and propafenone. In 2D simulations, disopyramide
and quinidine promoted re-entry termination by increasing the re-entry wavelength,
whereas propafenone induced secondary waves which destabilized the re-entrant circuit.
In 3D simulations, the DF of re-entry was reduced in a dose-dependent manner for
disopyramide and quinidine, and propafenone to a lesser extent. All of the anti-arrhythmic
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agents promoted pharmacological conversion, most frequently terminating re-entry in
the order quinidine > propafenone = disopyramide. Our findings provide further insight
into mechanisms of SQT1-related AF and a rational basis for the pursuit of combined IKr
and INa block based pharmacological strategies in the treatment of SQT1-linked AF.
Keywords: arrhythmia, short QT syndrome, atrial fibrillation, hERG, class I anti-arrhythmics, human atria,
potassium channels
INTRODUCTION
The short QT syndrome (SQTS) is characterized primarily
by a short QT interval on the ECG, which corresponds to
abbreviated ventricular repolarisation. However, symptomatic
atrial fibrillation (AF) has also been reported as a common
first clinical presentation of the SQTS (Schimpf et al., 2005),
suggesting that pathophysiological mechanisms leading to
shortening of the QT interval also affect the atria, which can
increase susceptibility to AF. The N588K mutation to the human
Ether-à-go-go-Related gene (hERG), which encodes the α subunit
of channels carrying rapid delayed rectifier potassium current,
IKr, underlies a form of SQTS variant 1 (SQT1) (Brugada et al.,
2004), and has been associated with a high incidence of AF
in affected probands—as high as 50% (Hu et al., 2017). Whilst
ventricular arrhythmia substrates in SQT1 have received much
attention (Zhang andHancox, 2004; Patel andAntzelevitch, 2008;
Adeniran et al., 2011), there have been comparatively fewer
studies investigating mechanisms by which SQT1 mutations
promote AF, which can be an important biomarker of the SQTS.
Furthermore, effective management of AF remains a challenge,
and is incompletely understood in the context of SQT1 (Enriquez
et al., 2016; Hancox et al., 2018).
A previous simulation study (Loewe et al., 2014b) used the
Courtemanche-Ramirez-Nattel (CRN) mathematical model of
the human atrial action potential (AP) (Courtemanche et al.,
1998) to demonstrate shortening of the atrial effective refractory
period (ERP) and tissue excitation wavelength (WL) consequent
to the N588K-hERG mutation. This was shown to facilitate
initiation and sustenance of spiral waves in idealized two-
dimensional (2D) sheets of human atrial tissue, which is a likely
mechanism for increased susceptibility to AF. However, both
the intrinsic electrical heterogeneities and complex anatomy
of the human atria have also been suggested to influence
arrhythmia vulnerability and dynamics in overall response
to K+ channel mutations (Colman et al., 2017; Whittaker
et al., 2017b). Consequently, the first aim of the present
study was to assess the arrhythmogenicity of the N588K-hERG
mutation in anatomically-detailed models of the human atria
with realistic structure and inclusion of regional differences in
electrophysiology.
The class Ia anti-arrhythmic drug quinidine is typically
used as the frontline therapy for QT interval normalization
in SQT1 (Gaita et al., 2004; Giustetto, 2006; Hu et al.,
2017), and disopyramide has been suggested as a possible
alternative (Dumaine and Antzelevitch, 2006; Schimpf et al.,
2007). Regarding management of atrial arrhythmias, the class
Ic anti-arrhythmic drug propafenone has been reported to
be effective at preventing recurrent episodes of (paroxysmal)
AF mediated by the N588K mutation to hERG (Hong et al.,
2005; Bjerregaard et al., 2006), maintaining 2 patients free of
arrhythmia recurrence for >2 years (Hong et al., 2005). In an
experimental setting in which a hERG activator was used to
approximate SQT1, quinidine (a blocker of INa and IKr) was
effective at extending atrial AP duration and ERP and preventing
AF (Nof et al., 2010), more so than E-4031 (a selective IKr
blocker) or lidocaine (an INa blocker) alone, suggesting that
K+ and Na+ channel blocking effects combine synergistically
for improved management of AF in SQT1. Similarly, in our
previous study, a multi-scale computational modeling approach
was used to investigate ventricular pharmacological effects of
disopyramide and quinidine in SQT1 (Whittaker et al., 2017a),
where combined INa and IKr block by both compounds was
shown to prolong ERP to a greater extent than INa or IKr block
alone. Mechanisms by which Na+ and K+-channel blocking
agents may provide beneficial effects in the context of SQT1-
mediated human atrial pro-arrhythmia remain unclear. A multi-
scale cardiac modeling approach is being used increasingly for
optimisation of therapy (Yuan et al., 2015). Consequently, the
second aim of the present study was to assess the efficacy of the
class I drugs disopyramide, quinidine, and propafenone on rate
and rhythm control of human atrial arrhythmias mediated by
SQT1, from cell to 3D tissue levels, using drug binding models
(including reduced potency of drugs against SQT1 mutant IKr)
with multi-channel pharmacology.
METHODS
Modeling Human Atrial Electrophysiology
Human atrial electrophysiology was simulated using the Colman
et al. model (Colman et al., 2013), as updated recently (Ni et al.,
2017), and is hereinafter referred to as the CNZ (Colman-Ni-
Zhang) model. The equations for IKr in the CNZ model were
replaced with previously developed and validated Markov chain
formulations of wild type (WT) and N588K mutant IKr/hERG
(Whittaker et al., 2017a). The maximal conductance of IKr was
set to gKr = 0.0111375·
[
K+
]0.59
o
, where
[
K+
]
o
is the extracellular
potassium concentration (Adeniran et al., 2011), resulting in an
action potential duration (APD) at 90% repolarisation (APD90)
of 248.8ms at 1Hz in the baseline human atrial cell model,
which is well within the experimentally-measured range of APDs
in human atrial myocytes (Bosch et al., 1999; Kim et al., 2002;
Dobrev and Ravens, 2003; Katoh et al., 2005; Redpath et al.,
2006; Pau et al., 2007). A family of regional human atrial cell
models was incorporated into the CNZ model, accounting for
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distinct differences in electrophysiology of the right and left
atrium (RA and LA, respectively), right and left atrial appendages
(RAA and LAA, respectively), crista terminalis (CT), pectinate
muscles (PM), atrio-ventricular ring (AVR), atrial septum (AS),
Bachmann’s bundle (BB), and pulmonary veins (PV) (Colman
et al., 2013). Changes to maximal ionic conductances relative
to the RA model implemented in order to create a family of
regional cell models are given in Table S1. The homozygous
(N588K) form of SQT1 was modeled as consisting of 100%
mutant subunits, whereas the heterozygous (WT-N588K) form
was assumed to consist of a 1:1 WT:mutant subunit ratio
(Whittaker et al., 2017a).
Modeling Pharmacological Actions of
Disopyramide and Quinidine
In our previous study (Whittaker et al., 2017a), the actions of
the class Ia anti-arrhythmic drugs disopyramide and quinidine
on human ventricles were simulated in the setting of SQT1.
State-dependent binding of disopyramide and quinidine to hERG
channels was simulated through addition of drug-bound open
and inactivated states to Markov chain formulations of IKr, and
the guarded receptor model (Starmer et al., 1984) was used to
describe use-dependent block of fast sodium current, INa, by both
agents. Furthermore, the blocking actions of disopyramide and
quinidine on slow delayed rectifier potassium current, IKs, L-
type calcium current, ICaL, transient outward potassium current,
Ito, inward rectifier potassium current, IK1 (quinidine only), and
late sodium current, INaL (quinidine only), were modeled using a
simple “pore block” approach. In the present study, the actions of
disopyramide and quinidine on human atrial electrophysiology
were represented using the same formulations and IC50 (half
maximal inhibitory concentration) values presented inWhittaker
et al. (2017a). In addition, disopyramide and quinidine have
both been reported to block the atrial-specific ultra-rapid delayed
rectifier potassium current, IKur. For disopyramide, the IC50 for
block of IKur was taken to be 25.0µM (Aréchiga et al., 2008), and
for quinidine the IC50 was taken to be 6.6µM, as measured in
human atrial myocytes (Nenov et al., 1998). As the CNZ model
does not include late sodium current, quinidine block of INaL
was not included in simulations. Full details of disopyramide and
quinidine models can be found in Whittaker et al. (2017a).
Modeling Pharmacological Actions of
Propafenone
Using the same approach as detailed for disopyramide and
quinidine in Whittaker et al. (2017a), state-dependent models
of drug block by propafenone were developed. Interactions
between propafenone and IKr/hERG were developed based on
experimental data obtained at 37◦C (Paul et al., 2002; McPate
et al., 2008), where estimation of parameters for drug-bound
states of the Markov chain formulation of IKr was performed
using the procedure outlined in Moreno et al. (2016). Binding
and unbinding rates to activated and inactivated state channels
were allowed to vary freely in order to minimize the difference
between simulated and experimental dose-dependent steady
state block (WT and N588K), mean fractional block of tail
currents during a pulse protocol, and voltage-dependence of
tail current block (Paul et al., 2002; McPate et al., 2008). The
extended drug-free Markov chain model of IKr/hERG is shown
in Figure 1, as well as the close concordance between simulated
and experimental data regarding propafenone block of IhERG.
Parameters and state affinities are given in Table S2.
Propafenone is a class Ic sodium channel blocking anti-
arrhythmic drug (Roden, 2014). Use-dependent block of sodium
channels by propafenone was represented using the guarded
receptor hypothesis (Starmer et al., 1984), as described for
disopyramide and quinidine. Propafenone is predominantly an
open state sodium channel blocker with little to no resting state
block (Edrich et al., 2005; Burashnikov et al., 2012), and was
thus assumed to bind only to activated and inactivated states.
Binding and unbinding parameters were constrained based on
the dose-dependent, use-dependent, and steady state block of INa
by propafenone (Harmer et al., 2008), as shown in Figure 2A.
Binding and unbinding parameters and state affinities are given
in Table S3.
Whilst propafenone most potently blocks IKr and INa, it is a
multi-channel blocker, and thus exerts secondary effects on other
ion channels, which were modeled using a simple pore block
based on IC50 values from the literature. Propafenone blocks
ICaL with an IC50 of 1.5–1.7µM in mammalian cardiac myocytes
(Fei et al., 1993; Hancox and Mitcheson, 1997). In human atrial
myocytes, propafenone has been shown to block Ito with an IC50
of 4.8µM (Gross and Castle, 1998; Seki et al., 1999) and IK1 with
an IC50 of 16.8µM (Amorós et al., 2013). Finally, IKur is blocked
with an IC50 of 4.4µM (Franqueza et al., 1998). The therapeutic
range of propafenone has been estimated to be between 2 and
6µM (Paul et al., 2002). Taking into account plasma protein
binding, estimates of the most likely unbound concentrations
have been given as 0.15–0.7µM (Slawsky and Castle, 1994), 0.2–
0.6µM (Duan et al., 1993), and 0.33–1µM (Seki et al., 1999).
In this study, the effects of three equally-spaced concentrations
which fell within this range were studied−0.2, 0.5, and 0.8µM
propafenone. It should be noted that these concentrations are
not intended to be compared directly with those chosen for
disopyramide and quinidine (1, 2, and 5µM), which were taken
from Whittaker et al. (2017a) and are not equally-spaced. A
comparison of IC50 values used for disopyramide, quinidine, and
propafenone is given in Table S4.
In order to assess whether the combined actions of
propafenone in the model induced reasonable rate- and
concentration- dependent effects on the AP under control
conditions, alterations in the maximum upstroke velocity
(V˙max) upon application of propafenone were compared with
experimental data taken from canine atrial cells (Burashnikov
et al., 2012). Figure 2B shows changes in V˙max upon application
of 0.3 and 1.5µM propafenone at cycle lengths of 500 and
300ms, where close concordance can be seen between simulation
and experiment (Figure 2C). Although experimental data were
taken from canine atrial myocytes, the human atrial simulation
data nonetheless recapitulated the considerable reduction in
V˙max at both concentrations and cycle lengths, which is
primarily due to the sodium channel blocking actions of
propafenone.
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FIGURE 1 | Propafenone interactions with hERG channels. (Ai) Drug-free and (Aii) drug-bound (additional states shown in green) Markov chain models of IKr/hERG.
Simulated (solid line) and experimental (points) mean fractional block by 0.5µM propafenone (PROPAF) of IhERG during pulse protocol (shown inset) (Bi), and
dose-response curve under WT (blue) and SQT1 mutant N588K (red) conditions (Bii), where IC50 values are 390 nM and 936 nM (2.4-fold increase), respectively. (Ci)
Simulated and (Cii) experimental current traces in response to a 10,000ms depolarising voltage step to 0mV from a holding potential of −80mV (Di,Dii) under
control conditions and with application of 0.5µM PROPAF – these data were used to validate and not to further train the model. Experimental data at 37◦C are taken
from Paul et al. (2002) and McPate et al. (2008).
Tissue Simulations
Propagation of excitation waves in tissue was described using the
monodomain equation,
∂V
∂t
= ∇ (D∇V)−
Iion
Cm
, (1)
where V is the transmembrane voltage, D is the global
conductivity tensor, Iion is the total ionic current, and Cm is
the membrane capacitance. Equation (1) was solved using a
finite difference PDE solver based on the explicit forward Euler
method and Strang splitting scheme. Effects of the N588K-hERG
mutation on ERP,WL, conduction velocity (CV), and spiral wave
dynamics were determined using 1D and 2Dmodels of RA tissue,
as described previously (Whittaker et al., 2017b, 2018). Spiral
waves were initiated in 2D models using an S1-S2 cross-shock
protocol, and spiral wave core trajectories over a 5.0 s simulation
period were traced by locating phase singularities (Bray and
Wikswo, 2002). The behavior of re-entrant excitations in an
anatomically-realistic setting was determined using a 3D human
atrial structured grid geometry based on the Visible Female
dataset (Seemann et al., 2006; Colman et al., 2013; Whittaker
et al., 2017b) with rule-based fiber orientations (Krueger et al.,
2011). The transverse value of the diffusion coefficient, D⊥, was
set to 0.1 mm2 ms−1, where an anisotropy ratio (D||:D⊥) of 3:1
in directions longitudinal and transverse to fibers was applied
in the atrial working myocardium, and a ratio of 9:1 along the
fast conducting bundles of the BB, CT, and PM (Colman et al.,
2013; Whittaker et al., 2017b), which gave global and specific
regional activation times in close agreement with experimental
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FIGURE 2 | Propafenone interactions with sodium channels. (Ai) Simulated (solid lines) and experimental (points) use-dependent block of sodium channels by
propafenone (PROPAF) elicited using a series of 8 pulses from −90mV to 0mV at 3Hz for three different test concentrations. (Aii) Steady state block of sodium
channels using pulses from −90mV to 0mV at 3Hz until a steady state was achieved. Experimental data are taken from Harmer et al. (2008), where the steady state
block IC50 value is given as 1.4µM. (B) Simulated and (C) experimentally-measured PROPAF-induced reduction in maximum upstroke velocity (V˙max) upon
application of 0.3 and 1.5µM PROPAF at a cycle length (CL) of (i) 500ms and (ii) 300ms. All V˙max reductions are relative to the control (C) value at a CL of 500ms.
Experimental data, recorded from canine atrial myocytes, are taken from Burashnikov et al. (2012).
measurements (Lemery et al., 2007). The activation (ACT) time
was defined as the time required for the membrane potential
to reach −20mV at each point in the geometry (Ni et al.,
2017). Activation-recovery interval (ARI) was defined as the time
interval between membrane potential depolarisation to −20mV
and repolarisation to −70mV (adjusted to −65mV in the PV
region due to higher resting membrane potential) (Ni et al.,
2017).
Re-entry was initiated using the phase distribution method
(Biktashev and Holden, 1998; Whittaker et al., 2017a), by
initiating either a clockwise or anti-clockwise scroll wave (as
seen from a RA posterior wall view). Where sustained re-entrant
activity was initiated, a power spectrum was obtained through
fast Fourier transform analysis of pseudo ECG (pECG) time
series (recorded from within the RA cavity). The dominant
frequency (DF) was computed in Matlab from the largest
peak in the power spectrum density. For simulating the
effects of disopyramide, quinidine, and propafenone on re-
entrant excitation, state variables for each node within the
3D anatomical model were saved after 2.5 s of a 10.0 s
episode of sustained re-entrant activity in drug-free conditions.
These were then used as initial conditions for new 3D
simulations of duration 7.5 s (giving 10.0 s activity overall)
in which varying concentrations of anti-arrhythmic drugs
(1, 2, or 5µM disopyramide and quinidine; 0.2, 0.5, or
0.8µM propafenone) were applied immediately. This gave 18
simulations in total; 3 doses for each of the 3 anti-arrhythmic
drugs, with 2 scroll wave initial conditions (both clockwise and
anti-clockwise).
RESULTS
Effects of SQT1 Mutant IKr on Human Atrial
Action Potentials
Both SQT1 mutant conditions shortened the human atrial
APD at a pacing rate of 1Hz (Figure 3Ai), from 248.8ms
in the WT condition to 195.4 and 163.3ms in heterozygous
(WT-N588K) and homozygous (N588K) mutation conditions,
respectively. This was due to loss of inactivation associated
with the N588K-hERG mutation, which increased IKr early
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FIGURE 3 | Effects of the N588K-hERG mutation at the single cell and whole human atria level. (Ai) Single cell action potential profiles under WT (blue), WT-N588K
(green), and N588K (red) conditions at a pacing frequency of 1Hz, with corresponding current traces for (Aii) IKr, (Aiii) IK1, (Aiv) IKs, and (Av) ICaL, and (Avi) a
summary of the measured APD90. (B) Activation-recovery interval (ARI) maps under (i) WT, (ii) WT-N588K, and (iii) N588K conditions. (Ci) View looking into the cavities
of the 3D anatomical human atria model, with the following regions highlighted: crista terminalis (CT), left atrium (LA), pectinate muscles (PM), pulmonary veins (PV),
and right atrium (RA). (Cii) Measured dispersion of activation-recovery interval, 1ARI, between different atrial regions under WT and SQT1 mutation conditions.
during the AP and served to accelerate the repolarisation
process (Figure 3Aii). Action potential abbreviation reduced
considerably the duration of the plateau phase, causing IK1
to contribute to terminal repolarisation earlier during the AP
(Figure 3Aiii), and lesser activation and reduced contribution of
IKs (Figure 3Aiv). The SQT1 mutation also decreased net ICaL
due to the abbreviated plateau phase (Figure 3Av), shortening
the APD90 under heterozygous and homozygous conditions
(Figure 3Avi). In tissue, accelerated repolarisation under SQT1
conditions shortened the ERP and consequently the excitation
WL. At the organ scale (in the 3D anatomical human atria
model), both heterozygous and homozygous forms of the
N588K-hERGmutation decreased global ARI (Figure 3B), whilst
preserving the global dispersion of ARI. Furthermore, whereas
1ARI was decreased between CT/PM regions, it was increased
between PV/LA and RA/LA regions under SQT1 conditions
(Figure 3C). A summary of the effects of the N588K-hERG
mutation on multi-scale human atrial AP biomarkers is given in
Table 1.
Scroll Wave Dynamics in 3D Anatomical
Human Atria Geometry
A summary of 3D scroll wave simulations in the anatomical
human atria model under WT and SQT1 mutation conditions
(in a clockwise configuration from a RA posterior wall aspect)
is given in Figure 4. In the WT condition, scroll waves followed
2 transient, fragmented circuits around the RA, before self-
terminating at ∼0.7 s (Video S1), which precluded accurate
measurement of the DF. In the WT-N588K condition, re-
entrant wave activity sustained for the entire 10.0 s with a
DF of 4.99Hz, and was driven mostly by a macro re-entrant
circuit around the right AVR, whilst also showing CT/isthmus
driven activity in the RA (Video S2). Under homozygous
N588K mutation conditions, scroll wave activity was also driven
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TABLE 1 | A summary of multi-scale simulation results.
Single cell 1D 3D
APD90 (ms) APD50 (ms) ERP (ms) WL (ms) 1ARI (ms) DF (Hz)
WT 248.8 144.6 273 198.9 77 4.19*
WT-N588K 195.4 100.3 218 158.4 77 4.99
N588K 163.3 75.3 187 135.7 71 5.59
Analysis biomarkers at the single cell, 1D, and 3D levels under WT, WT-N588K, and N588K conditions at a pacing rate of 1Hz.1ARI refers to global dispersion of ARI. DF was measured
from the first 5.0 s of activity. APD90 and APD50, Action Potential Duration at 90% and 50% repolarisation respectively; ERP, Effective Refractory Period; WL, Excitation Wavelength;
ARI, Activation-Recovery Interval; DF, Dominant Frequency. The DF is an average computed from two simulations with clockwise and anti-clockwise initial conditions, except in the case
marked with *, in which only one value was used.
FIGURE 4 | Scroll waves under WT and SQT1 mutation conditions in the 3D
anatomical human atria model. (i) Evolution of scroll waves following initiation
of re-entry in a clockwise configuration (from a RA posterior wall aspect) at
times t = 100ms, t = 1,000ms, t = 5,000ms, and t = 10,000ms under (A)
WT, (B) WT-N588K, and (C) N588K conditions, with (ii) corresponding pseudo
ECGs taken from the first 5.0 s of re-entry simulations.
predominantly by a re-entrant circuit around the AVR, with
occasional existence of multiple waves on the RA free wall
(Video S3), and a DF of 5.59Hz. A summary of simulations
using anti-clockwise scroll wave initial conditions is shown in
Figure S1, and an average of the DF from both simulations
(where applicable)measured from the first 5.0 s of activity is given
in Table 1.
Effects of Class I Drugs on Human Atrial
Action Potentials
In order to assess the actions of class I anti-arrhythmic drugs on
the human atria at the cellular level, the effects of applying various
concentrations of disopyramide, quinidine, and propafenone
were investigated on the single cell AP under heterozygous WT-
N588K (hereinafter referred to simply as SQT1) conditions.
Figure 5 shows AP profiles under drug-free SQT1 conditions and
upon application of different concentrations of each drug at a
pacing frequency of 1Hz, with corresponding fractional block of
IKr and INa. Application of all concentrations of disopyramide
and propafenone produced only modest prolongation of the
APD, failing to restore it to that of the WT condition. Quinidine,
on the other hand, was more effective at prolonging the APD
due to extensive IKr block, with the highest concentration (5µM)
prolonging the APD beyond that of the WT level. In contrast,
all three agents prolonged the ERP effectively, restoring it to
(or exceeding) that of the WT level at the highest respective
concentrations tested, due to additional ERP-prolonging effects
of INa block.
Conduction slowing due to sodium channel block by the
three drugs caused an increase in activation time in the 3D
anatomical human atria model (Figure 5D), which was most
prominent for quinidine and least prominent for propafenone
at the concentrations tested. A summary of the effects of
pharmacological modulation across multiple scales is given in
Table 2. In addition, in the 1D tissue model, the rate-dependent
effects of disopyramide, quinidine, and propafenone on the ERP,
CV, and WL are shown in Figure S2. Quinidine was shown to
produce the most potent effects on CV and ERP at all pacing
rates. Propafenone exerted the weakest effects on ERP at fast
pacing rates, but had the greatest propensity to promote beat-to-
beat alternans.
Pharmacological Effects of Class I Drugs
on Re-entry Dynamics
In 2D simulations, under drug-free WT conditions the initiated
spiral wave failed to re-enter the tissue (not shown). Under
drug-free SQT1 conditions, the initiated spiral wave sustained
for the 5.0 s duration of the simulation, eventually settling into
a stationary, epicycloidal trajectory (Figure 6Ai). Application
of 5µM disopyramide was sufficient to terminate re-entry, as
the re-entry wavelength was increased to such an extent that
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FIGURE 5 | Effects of class I drugs on human atrial electrophysiology in SQT1. Effects of (A) disopyramide (DISO), (B) quinidine (QUIN), and (C) propafenone
(PROPAF) on (i) single human atrial cell action potentials (APs) under wild type (WT) conditions (blue, dashed line), drug-free WT-N588K (SQT1) conditions (green, solid
line), and SQT1 + varying drug concentrations (purple, orange, and red solid lines). Corresponding fractional block of (ii) IKr and (iii) INa, and (iv) increase in APD90 (red)
and effective refractory period (ERP; blue). (D) Activation sequences in the 3D anatomical human atria model under (i) drug-free SQT1 (control – C), (ii) SQT1 + 2µM
DISO, (iii) SQT1 + 2µM QUIN, and (iv) SQT1 + 0.5µM PROPAF conditions, with corresponding (E) activation (ACT) time summarized as a barchart. All simulations
performed at a basic cycle length of 1,000ms.
the spiral wave meandered out of the tissue (Figure 6Aii).
On the other hand, both 1 and 2µM disopyramide did not
terminate re-entrant activity, but did increase the area over
which spiral waves meandered (from 0.35 mm2 ms−1 in the WT
condition to 0.40 and 0.47 mm2 ms−1, respectively ’(Figure 6B).
Similarly, 1µM quinidine increased the area of meander to 0.44
mm2 ms−1 without terminating re-entry, whereas 2 and 5µM
quinidine terminated re-entry without inducing wave break
(Figure 6C). Application of 0.2 and 0.5µMpropafenone resulted
in termination of re-entry by decreasing both the stationarity
and stability of spiral waves (Figure 6D), whereas 0.8µM
propafenone did not terminate re-entry but did destabilize the
re-entrant circuit and substantially increase the area of meander
(to 0.75 mm2 ms−1).
In 3D simulations using clockwise scroll wave initial
conditions, quinidine terminated re-entry at all concentrations,
and disopyramide terminated re-entry at concentrations of 1
and 5µM (arrhythmia termination by 5µM disopyramide and
2µM quinidine are shown in Videos S4, S5, respectively).
At a concentration of 2µM disopyramide, the DF was
reduced from 4.79 to 3.99Hz (measured from the final 5.0 s of
activity). Propafenone, on the other hand, was comparatively
ineffective at reducing the DF at the concentrations tested, but
terminated re-entry at a concentration of 0.5µM (Video S6).
Representative examples of arrhythmia termination by
disopyramide, propafenone, and quinidine are shown in
Figure 7. Disopyramide and quinidine produced a dose-
dependent decrease in the DF which was greater than for
propafenone (Figure 7C). In an anti-clockwise scroll wave
configuration, the efficacy of anti-arrhythmic drugs was less
favorable, with pharmacological conversion of re-entrant waves
occurring only for 0.5µM propafenone and 5µM quinidine. A
quantitative summary of all 2D and 3D re-entry simulations is
given in Table S5.
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TABLE 2 | A summary of multi-scale pharmacological simulation results.
Single cell 1D 3D
APD90 (ms) ERP (ms) CV (cm/s) WL (mm) ACT time (ms)
Drug-free SQT1 195.4 218 72.7 158.4 135
DISO (µM) 1 199.3 227 68.7 155.9 146
2 203.6 236 65.4 154.3 156
5 218.4 271 57.8 156.5 186
QUIN (µM) 1 221.5 253 66.6 168.4 153
2 242.6 286 61.6 176.1 174
5 298.3 419 49.4 207.2 199
PROPAF (µM) 0.2 206.9 233 72.0 167.8 138
0.5 218.6 253 70.6 178.7 147
0.8 227.4 271 69.1 187.4 152
Analysis biomarkers at the single cell, 1D, and 3D levels at a pacing rate of 1Hz under drug-free SQT1 conditions, and upon application of various concentrations of disopyramide
(DISO), quinidine (QUIN), and propafenone (PROPAF). APD90, Action Potential Duration at 90% repolarisation ; ERP, Effective Refractory Period; CV, Conduction Velocity; ACT time,
Activation Time.
DISCUSSION
In this study, pathophysiological effects of the SQT1-related
N588K-hERG mutation on human atrial electrophysiology were
assessed, investigating mechanisms of increased susceptibility
to the development of atrial arrhythmias in multi-scale cellular
and tissue models incorporating electrical and anatomical
heterogeneities. Furthermore, the actions of the class I anti-
arrhythmic drugs disopyramide, quinidine, and propafenone
were assessed in the context of sustained atrial arrhythmic
excitations mediated by the SQT1 N588K mutation using
drug simulations including binding kinetics, altered potency of
IKr/hERG block in SQT1, and multiple ion channel block. Both
quinidine and disopyramide have demonstrated efficacy in QT
interval prolongation in the setting of SQT1 (Gaita et al., 2004;
Schimpf et al., 2007; Mizobuchi et al., 2008; Giustetto et al.,
2011; Hu et al., 2017), whereas propafenone has been used in 3
patients for management of episodes of paroxysmal AF mediated
by SQT1, which prevented recurrence of arrhythmias but did
not prolong the QT interval (Hong et al., 2005; Bjerregaard
et al., 2006). This study provides clinically-relevant insights into
pharmacology of SQT1 by evaluating and comparing the actions
of all three drugs in the context of accelerated atrial repolarisation
and arrhythmias mediated by SQT1, offering an important step
toward in silico optimisation of pharmacological therapy in this
context.
Main Findings
The major findings presented in this study are as follows.
(1) Heterozygous and homozygous forms of the SQT1-linked
N588K-hERG mutation shortened significantly the APD of
human atrial cells, whilst preserving global dispersion of ARI,
and increasing 1ARI between certain regions of the human
atria. (2) The dominant frequency and lifespan of re-entry in
3D arrhythmia simulations was increased by heterozygous and
homozygous forms of the N588K mutation. (3) Disopyramide,
quinidine, and propafenone all produced ERP prolongation
in the setting of SQT1, the extent of which was greatest for
quinidine. (4) In 2D simulations, disopyramide and quinidine
terminated re-entry at high concentrations due to increased re-
entry wavelength, whereas propafenone terminated re-entry in a
non-dose-dependent manner, by inducing secondary waves. (5)
In 3D simulations, the DF of re-entry was reduced in a dose-
dependent manner for clinically-relevant doses of disopyramide
and quinidine, and propafenone to a lesser extent. (6) All
three anti-arrhythmic agents demonstrated some efficacy in
pharmacological rhythm control, most frequently terminating re-
entry in the order quinidine > propafenone = disopyramide. A
summary of findings regarding pro-arrhythmic mechanisms of
the N588K-hERG mutation in human atria and anti-arrhythmic
actions of selected class I drugs is given in Figure 8.
SQT1 Mutant IKr Promotes Human Atrial
Arrhythmogenesis
The fact that the N588K-hERG mutation is associated with
both a short QT interval and reports of AF (Hong et al.,
2005) suggests that pathophysiological mechanisms leading to
QT interval shortening in SQT1 also affect the atria and may
promote AF. In an experimental model of SQT1, application
of 20µM of the IKr agonist PD-118057 shortened the APD in
both CT and PM cell types of canine atrial tissue (Nof et al.,
2010), as well as increasing APD dispersion between them. In the
present study, at the cellular level heterozygous and homozygous
forms of the N588K-hERG mutation produced a shortening of
the human right atrial APD of 53.4 and 85.5ms, respectively–
values which are consistent with a previous simulation study
(Loewe et al., 2014b). At the tissue level, global 1ARI was
unaffected by the WT-N588K mutation condition, and was
slightly decreased by the homozygous form. The model predicted
an increase in1ARI between PV/LA and RA/LA regions for both
heterozygous and homozygous forms of the N588K mutation
(Figure 3C), but not between CT/PM regions. This may be due
to the fact that the effects of the hERG activator PD-118057 and
of the N588K mutation on IKr/hERG are different: the former
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FIGURE 6 | Re-entry dynamics in homogeneous 2D sheets upon application of disopyramide, propafenone, and quinidine in SQT1 mutation conditions. (A)
Representative snapshots of re-entrant spiral waves under (i) drug-free SQT1 and (ii) SQT1 + 5µM disopyramide (DISO) conditions at times, t = 250, 500, 750, and
1,000ms following re-entry initiation, with spiral wave core trajectories superimposed onto membrane potentials in black. Spiral wave core trajectories over a
5,000ms period under (Bi, Ci, Di) drug-free SQT1 conditions, and upon application of (Bii) 1µM, (Biii) 2µM, and (Biv) 5µM DISO, (Cii) 1µM, (Ciii) 2µM, and (Civ)
5µM quinidine (QUIN), and (Dii) 0.2µM, (Diii) 0.5µM, and (Div) 0.8µM propafenone (PROPAF).
increases IKr/hERG channel open probability without altering
gating kinetics (Zhou et al., 2005), whereas the latter alters
kinetics through profound attenuation of inactivation (Cordeiro
et al., 2005; McPate et al., 2005).
Interestingly, there is clinical evidence of a LA-RA gradient
in the DF in paroxysmal AF (Lazar et al., 2004), which may
be underlain by APD differences between the RA and LA
in pathological conditions which promote AF (Voigt et al.,
2010). Furthermore, regional differences in APD between PV/LA
regions have been identified previously as high frequency
excitation or microreentrant sources underlying AF (Mandapati
et al., 2000; Arora et al., 2003; Kumagai et al., 2004)–this suggests
that localized increases in the spatial dispersion of repolarisation
could be a mechanism by which atrial arrhythmogenesis is
promoted in SQT1, as suggested in the previous experimental
study (Nof et al., 2010).
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FIGURE 7 | Arrhythmia termination in 3D anatomical human atria by representative concentrations of disopyramide, propafenone, and quinidine under SQT1 mutation
conditions. (A) Snapshots of re-entrant scroll waves in a clockwise configuration (viewed from RA posterior wall) at various time points after initiation of a scroll wave in
the 3D anatomical human atrial model under (i) drug-free WT-N588K conditions, and upon application of (ii) 5µM disopyramide (DISO), (iii) 0.5µM propafenone
(PROPAF), and (iv) 2µM quinidine (QUIN) conditions, with (B) corresponding pseudo ECG recorded during the final 5.0 s. In pharmacological simulation drugs were
applied at t = 2,500ms. (C) Barcharts summarizing DF upon application of various concentrations of (i) DISO, (ii) PROPAF, and (iii) QUIN for clockwise and
anti-clockwise initial conditions (ICs 1 and ICs 2, respectively). * denotes simulations in which DF was not calculated due to occurrence of re-entry termination.
In a previous simulation study (Loewe et al., 2014b), the
N588K-hERGmutation in a 1:1mutant toWT ratio was shown to
increase inducibility and lifespan of rotors in idealized 2D sheets
of human atrial tissue, but did not permit sustained re-entry.
By contrast, in the present study, the heterozygous WT-N588K
(SQT1) condition permitted the sustenance of spiral waves in
2D simulations. This may be due to several differences in the
modeling, one of which is that the CRN model used in that
study (Loewe et al., 2014b) produces an ERP restitution curve
which is around 50ms higher than available experimental data
(Wilhelms et al., 2013), making re-entry more difficult to sustain,
whereas the CNZ model ERP restitution curve lies mostly within
the experimental range (Figure S3). In this study, the presence
of realistic structure and heterogeneous electrophysiology, in
addition to the cellular electrophysiological substrate induced by
the N588K-hERG mutation, also favored the sustenance of re-
entrant scroll waves in the 3D anatomical human atria model
(using both clockwise and anti-clockwise scroll wave initial
conditions), and could both prolong or shorten the lifespan
of re-entrant excitations under pharmacological modulation
conditions when compared directly to observations in 2D
homogeneous sheets. This highlights the value of including both
approaches in probing the arrhythmia substrate associated with
genetic mutations in human atria, as behavior in heterogeneous
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FIGURE 8 | A schematic summary of pro-arrhythmic effects of the
N588K-hERG mutation in human atria and anti-arrhythmic effects of class I
drugs. At the ion channel level, the N588K mutation impairs hERG channel
inactivation, increasing IKr which shortens the action potential duration (APD)
at the cellular level, and increases its dispersion, 1APD, between certain
regions of the human atria. In tissue, shortened APD corresponds to
shortened effective refractory period (ERP) and excitation wavelength (WL),
promoting sustenance of arrhythmias at the organ scale through higher
dominant frequency (DF) and lifespan (LS) of re-entry. Class I drugs
disopyramide (DISO), quinidine (QUIN), and propafenone (PROPAF) exert
effects at the ion channel level by blocking IKr and INa, in addition to
secondary actions. This prolongs APD and ERP, and reduces maximum
upstroke velocity (MUV) and conduction velocity (CV) at the cellular and tissue
levels, respectively. At the organ scale these pharmacological actions promote
arrhythmia rate and rhythm control through reduced DF and LS of re-entry.
3D anatomical models cannot necessarily be predicted from
homogeneous 2D simulations, and vice versa. It should be
noted nonetheless that electrical activity observed in 3D re-
entry simulations in this study remained relatively organized and
generally not driven by multiple wavelets. This lack of complex,
chaotic behavior which is observed in persistent AF is consistent
with reports of paroxysmal AF in some patients with the N588K-
hERG mutation (Hong et al., 2005) – addition of electrical and
intracellular gap junction remodeling or fibrosis in patients may
be required to promote degeneration of paroxysmal AF into
persistent AF.
Class I Drugs May Represent Useful
SQT1-Specific Pharmacotherapy for AF
Despite the prevalence of AF and decades of research, anti-
arrhythmic therapies for AF continue to have limited efficacy
and safety (Workman et al., 2011). In this study, the class I anti-
arrhythmic drugs disopyramide, quinidine, and propafenone
were shown to be only moderately effective in the management
of atrial arrhythmias mediated by the SQT1-linked N588K-
hERG mutation, although it should be noted that the 7.5 s
duration of 3D drug simulations is much shorter than
clinical time scales. Pharmacological rhythm control occurred
under application of both disopyramide and quinidine, but
in an unpredictable, non-dose-dependent way, as observed in
our previous in silico study (Whittaker et al., 2017a). One
mechanism of re-entry termination involving reduction of the
excitable gap under application of 5µM quinidine is shown in
Figure S4.
Both disopyramide and quinidine reduced consistently the
DF of re-entry in a dose-dependent manner, although as in
(Whittaker et al., 2017a) quinidine was more effective than
disopyramide at rate control in the setting of SQT1, likely due
to its more potent block of IKr (McPate et al., 2008) and INa
(Koumi et al., 1992). Propafenone was comparatively ineffective
at controlling the rate of atrial arrhythmias under the WT-
N588K mutation condition, although did demonstrate some
efficacy in re-entry termination. Figure S5 shows a mechanism
of pharmacological rhythm control by 0.5µM propafenone, in
which secondary waves induced by propafenone extinguished
all re-entrant pathways. This is consistent with the use of
propafenone to manage paroxysmal AF in SQT1 patients (Hong
et al., 2005; Bjerregaard et al., 2006), which maintained 3 patients
free of arrhythmia recurrence during follow up. However, as
propafenone has been reported to have no prolonging effect
on the QT interval in the setting of SQT1 (Hong et al.,
2005)— an effect which was demonstrated with variable success
using two leading human ventricle models (ten Tusscher and
Panfilov, 2006; O’Hara et al., 2011) in Figure S6—it is likely
that quinidine and disopyramide will remain more suitable
pharmacotherapies.
In this study, cellular and tissue level simulations (in a
1D model) alone did not serve as good predictors of the
overall effects of anti-arrhythmic drugs in the electrically-
heterogeneous, 3D anatomical whole atria model, consistent
with previous modeling studies (Varela et al., 2016; Whittaker
et al., 2017b). For example, disopyramide was shown not
to strongly affect the excitation WL in RA tissue (Table 2;
Figure S2), and yet it decreased reliably the DF of re-entrant
excitations under heterozygous N588K mutation conditions
in 3D simulations. This is likely due to the fact that
scroll waves were largely anatomically driven by a typical
macro re-entrant atrial flutter/tachycardia circuit (Lee et al.,
2012) which was larger than the functional WL; effects of
disopyramide on CV were thus more important. In contrast,
propafenone produced only modest changes to the CV and
was thus less effective at rate control in the model, but did
terminate re-entry under conditions in which the re-entrant
circuit was abolished by interaction with secondary waves
(Figure S5).
Insights Into the Efficacy of Class I Drugs
in SQT1
Further support for quinidine as a useful pharmacotherapy for
AF in the setting of SQT1 comes from the experimental use
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of the IKr agonist PD-118057 model (Nof et al., 2010). That
study suggested that the combined blocking actions on IKr and
INa are what made quinidine effective at preventing sustained
AF in canine right atrial tissue preparations, as neither IKr
nor INa block alone (by E-4031 or lidocaine, respectively) was
effective at terminating AF. Similarly, in our previous simulation
study of ventricular pharmacotherapy for SQT1 we showed that
combined block of INa and IKr by disopyramide and quinidine
prolonged the ERP to a greater extent than block of INa or
IKr alone (Whittaker et al., 2017a). In this study, we sought
to determine whether the greater ERP prolongation associated
with the synergistic combination of INa and IKr block by class
I drugs would also translate to greater efficacy in terminating
re-entry in a 2D sheet of SQT1 mutant human atrial tissue.
Figure S7 shows that the actions of 5µM of a hypothetical drug
with disopyramide kinetics for INa and IKr block were able to
terminate re-entry, whereas INa or IKr block alone did not, as
combined block produced the greatest prolongation of the ERP.
The spiral wave trajectories highlight the fact that INa block
in particular destabilized the re-entrant circuit, which, when
combined with IKr block, caused the spiral wave to meander out
of the tissue boundaries (Video S7). The findings from in silico
and in vitro experiments thus suggest that the combination of
prolonged APD and refractoriness arising from K+ and Na+
channel inhibition is likely to be valuable in the setting of SQT1.
Though selective blockers of IKs and IK1 are not yet clinically-
available, this combination may also warrant investigation as
a pharmacotherapeutic strategy for other forms of K+-linked
SQTS (SQT2 and SQT3).
LIMITATIONS
There are a number of limitations of the simulations presented
in this study. The 3D anatomical human atria model which
was employed for simulations in this study incorporated rule-
based fiber orientations (Krueger et al., 2011), which may not
capture sufficiently the complex cardiac microstructure of the
human atria (Stephenson et al., 2017) which could contribute
to the arrhythmia substrate. Whilst several hERG mutations
have now been identified in SQT1 (Hancox et al., 2018), the
present study focused only on the N588K-hERGmutation (which
produces a more marked effect on hERG kinetics than some
other mutations, Hancox et al., 2018), so the results here may
not apply to all forms of SQT1. However, recently the S631A-
hERG mutation (previously engineered for hERG structure-
function studies), which produces a similar extent of attenuation
of inactivation to N588K-hERG (McPate et al., 2008) has been
reported in an SQT1 family (Akdis et al., 2018), and thus the
findings of this study are likely also to be relevant to that
form of SQT1. An additional potential limitation arises from
the fact that mechanical contraction was not considered, which
has been reported previously to be impaired in the setting of
SQT1 in single human atrial cell simulations (Whittaker et al.,
2015) as well as in organ-scale ventricle simulations (Adeniran
et al., 2013), and based on clinical measurements (Frea et al.,
2015).
The models of disopyramide and quinidine used in this
study were adopted from (Whittaker et al., 2017a), in which
the effects of anti-arrhythmic drugs were assessed in the
setting of SQT1 in the human ventricles. However, both
agents also exhibit modest anti-cholinergic effects in the atria
(Nakajima et al., 1989) which were not accounted for, due
to the absence of a formulation for acetylcholine-activated
potassium current, IK,ACh, in the CNZ model. Similarly, the β-
adrenergic receptor blocking effects of propafenone were not
considered (McLeod et al., 1984). Inclusion of these factors
could give some insight into the response of the SQT1
phenotype to anti-arrhythmic drugs in the presence of autonomic
modulation, and could give more favorable results in terms
of arrhythmia prevention, especially for propafenone, which
may be particularly effective against AF triggered by increased
vagal tone. In addition, dynamic effects of agents due to the
influence of circadian variations in drug concentration and
heart rate on bioavailability were not investigated, which can
give further insights into differing clinical efficacies of drugs
(Loewe et al., 2014a). In relation to this, a further, more
general limitation is that translation of drug concentrations
from experiments and computer simulations to meaningful
clinical concentrations is potentially problematic. Finally, whilst
the 1:1 mutant to WT ratio, which was intended to represent
the heterozygous state of the proband, may represent an
oversimplification of the real hERG channel population in
SQT1, the approach adopted in this and our previous studies
(Adeniran et al., 2011, 2017; Whittaker et al., 2017a) reproduced
quantitatively QT interval shortening and T wave morphology
in SQTS conditions which was concordant with clinical
observations.
CONCLUSIONS
The simulations performed in this study further substantiate a
causative link between the SQTS-related N588K mutation and
APD/ERP shortening in human atria, as well as increased spatial
dispersion of repolarisation, which promotes development
of AF. In 3D human atria simulations which included
heterogeneous anatomy and electrophysiology, the N588K
mutation was shown to increase the dominant frequency
and lifespan of re-entrant excitation beyond that observed
in WT conditions. Pharmacological simulations demonstrated
that disopyramide and quinidine were more effective at
rate control than propafenone in the setting of SQT1, and
quinidine was most effective at rhythm control. Combined
block of INa and IKr by a hypothetical drug was shown
to be more beneficial in terms of re-entry termination in
a 2D sheet of human atrial tissue than IKr or INa block
alone in this context, suggesting useful targets for future
pharmacotherapies. Themulti-scale integrative cardiac modeling
approach adopted in this study serves as a useful paradigm for
optimisation of pharmacological therapy, allowing investigation
of how genetic defects at the ion channel level influence
organ scale propagation, arrhythmogenesis, and response to
pharmacotherapies.
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